沙丁胺醇與異丙托溴胺聯(lián)合霧化吸入治療支氣管哮喘急性發(fā)作的臨床效果觀察

黃燕虹

[摘要]目的 探討沙丁胺醇與異丙托溴胺聯(lián)合霧化吸入治療支氣管哮喘急性發(fā)作的臨床療效。 方法 選取2011年12月～2013年12月在我院進(jìn)行治療的82例支氣管哮喘急性發(fā)作患者，隨機(jī)分為觀察組和對照組，對照組給予常規(guī)治療和沙丁胺醇霧化吸入治療，觀察組在對照組治療的基礎(chǔ)上，加用異丙托溴胺霧化吸入進(jìn)行治療，比較兩組的療效。 結(jié)果 觀察組顯效率為61.90%，總有效率為95.24%，對照組顯效率為30.00%，總有效率為77.50%，兩組差異有統(tǒng)計(jì)學(xué)意義（P<0.05）。 結(jié)論 沙丁胺醇與異丙托溴胺聯(lián)合霧化吸入治療支氣管哮喘急性發(fā)作，可顯著增加治療效果。

[關(guān)鍵詞]沙丁胺醇；異丙托溴胺；氧驅(qū)動(dòng)霧化吸入；支氣管哮喘急性發(fā)作

[中圖分類號(hào)]R725.6 [文獻(xiàn)標(biāo)識(shí)碼]B [文章編號(hào)]2095-0616（2014）20-145-04

The clinical effect of salbutamol and ipratropium bromide combined with aerosol inhalation in treatment of acute attack of bronchial asthma

HUANG Yanhong

Tanwei Center Hospital of Lingshan Country， Lingshan 535413， China

[Abstract]Objective To investigate the clinical therapeutic effect of the salbutamol and ipratropium bromide combined with aerosol inhalation in treatment of acute attack of bronchial asthma. Methods We Selected 82 cases of bronchial asthma patients with acute onset， who was in our hospital for treatment from December 2011 to December 2013. They were randomly divided into the observation group and the control group， the control group were given routine treatment and salbutamol atomization inhalation treatment. Added the ipratropium bromide aerosol inhalation treatment to the treatment of the control group in observation group. Compared the two groups of the treatment efficacy. Results In the observation group， the significant effective rate was 61.90%， the total effective rate was 95.24%， in the control group， the significant effective rate was 30%， the total effective rate was 77.50%. There was significant difference between the two groups （P<0.05）. Conclusion Salbutamol and ipratropium bromide combined atomization inhalation in the treatment of acute attack of bronchial asthma， can significantly increase the therapeutic effect.

[Key words]Salbutamol； Ipratropium bromide； Oxygen atomizing aerosol inhalation； Acute attack of bronchial asthma

支氣管哮喘是一種以嗜酸粒細(xì)胞、肥大細(xì)胞反應(yīng)為主的氣道變應(yīng)性炎癥和氣道高反應(yīng)性為特征的疾病。臨床上表現(xiàn)為復(fù)發(fā)作性伴有哮鳴音的呼氣性呼吸困難、胸悶或咳嗽，可自行或治療后緩解。若長期反復(fù)發(fā)作可使氣道重塑，導(dǎo)致氣道增厚與狹窄，臨床上屬于危急重癥，嚴(yán)重者可導(dǎo)致窒息而死亡，嚴(yán)重威脅著患者的健康和生命[1]。本文就我院進(jìn)行治療的82 例支氣管哮喘急性發(fā)作患者進(jìn)行研究，現(xiàn)報(bào)道如下。

1 資料與方法

1.1 一般資料

選取2011年12 月～2013年12 月在本院進(jìn)行治療的82例支氣管哮喘急性發(fā)作患者，經(jīng)過患者及醫(yī)院倫理委員會(huì)通過，隨機(jī)分為觀察組和對照組，觀察組42例，男23例，女19例；年齡18～67歲，平均（42.5±2.1）歲；病程0.4～7.8年，平均（4.90±1.38）年；輕度哮喘7例，中度哮喘25例，重度哮喘10例；對照組40例，男22例，女18例；年齡19～68歲，平均（43.3±2.6）歲；病程0.3～7.5年，平均（5.13±1.42）年。輕度哮喘7例，中度哮喘24例，重度哮喘9例。兩組患者在性別組成、年齡、病程、病情程度等方面差異無統(tǒng)計(jì)學(xué)意義（P>0.05 ），具有可比性。